Insulet, Amgen form agreement

BEDFORD, Mass. - Under a five-year agreement announced Dec. 10, Insulet will supply biotech company Amgen with a device to deliver medications. Insulet makes the OmniPod insulin management system. “We are thrilled to advance our collaboration with Amgen to supply this version of our technology,” said Duane DeSisto, Insulet president and CEO, in a release. “Insulet's current device, the OmniPod, is a unique drug platform that provides the ability to vary the rate at which medication is infused.”